Edgewise Total Current Liabilities from 2010 to 2025
| EWTX Stock | USD 28.00 0.42 1.48% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 19.3 M | Current Value 10.9 M | Quarterly Volatility 6.8 M |
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 17.1 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.07. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
Edgewise | Total Current Liabilities |
Latest Edgewise Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Edgewise Therapeutics over the last few years. Total Current Liabilities is an item on Edgewise Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Edgewise Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Edgewise Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Edgewise Total Current Liabilities Regression Statistics
| Arithmetic Mean | 5,605,179 | |
| Geometric Mean | 2,724,058 | |
| Coefficient Of Variation | 120.64 | |
| Mean Deviation | 5,749,372 | |
| Median | 1,132,000 | |
| Standard Deviation | 6,761,917 | |
| Sample Variance | 45.7T | |
| Range | 18.2M | |
| R-Value | 0.80 | |
| Mean Square Error | 17.5T | |
| R-Squared | 0.64 | |
| Significance | 0.0002 | |
| Slope | 1,139,364 | |
| Total Sum of Squares | 685.9T |
Edgewise Total Current Liabilities History
About Edgewise Therapeutics Financial Statements
Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 19.3 M | 10.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.